StageZero Life Sciences Ltd.
SZLSF
$0.0021
-$0.025-92.25%
| 09/30/2024 | 06/30/2024 | 09/30/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 38.52% | -68.13% | -104.71% | -104.71% | -104.71% |
| Total Depreciation and Amortization | -138.13% | 139.34% | -36.07% | -36.07% | -36.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 269.20% | -201.54% | 732.37% | 732.37% | 732.37% |
| Change in Net Operating Assets | -48.27% | 189.53% | 82.04% | 82.04% | 82.04% |
| Cash from Operations | 116.38% | 32.29% | 573.24% | 573.24% | 573.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -19.59% | -- | -- | -- |
| Total Debt Repaid | 50.16% | 50.70% | 60.56% | 60.56% | 60.56% |
| Issuance of Common Stock | -- | -- | -90.94% | -90.94% | -90.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -120.36% | 8.32% | -520.57% | -520.57% | -520.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.50% | 173.08% | -243.73% | -243.73% | -243.73% |
